X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA PIRAMAL ENTERPRISES PLETHICO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -1.1 10.3 - View Chart
P/BV x 0.0 1.8 0.9% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PLETHICO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-18
PLETHICO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3953,083 12.8%   
Low Rs311,902 1.6%   
Sales per share (Unadj.) Rs604.4589.7 102.5%  
Earnings per share (Unadj.) Rs32.5284.0 11.4%  
Cash flow per share (Unadj.) Rs51.3310.5 16.5%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs473.61,467.0 32.3%  
Shares outstanding (eoy) m34.08180.27 18.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.44.2 8.3%   
Avg P/E ratio x6.68.8 74.8%  
P/CF ratio (eoy) x4.28.0 51.7%  
Price / Book Value ratio x0.51.7 26.5%  
Dividend payout %08.8 0.0%   
Avg Mkt Cap Rs m7,262449,332 1.6%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m1,59619,881 8.0%   
Avg. sales/employee Rs ThNM15,535.6-  
Avg. wages/employee Rs ThNM2,905.4-  
Avg. net profit/employee Rs ThNM7,482.5-  
INCOME DATA
Net Sales Rs m20,598106,310 19.4%  
Other income Rs m3862,595 14.9%   
Total revenues Rs m20,984108,906 19.3%   
Gross profit Rs m2,81851,599 5.5%  
Depreciation Rs m6424,773 13.5%   
Interest Rs m1,59329,783 5.3%   
Profit before tax Rs m96919,638 4.9%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138-28,764 0.5%   
Profit after tax Rs m1,10751,203 2.2%  
Gross profit margin %13.748.5 28.2%  
Effective tax rate %-14.3-146.5 9.8%   
Net profit margin %5.448.2 11.2%  
BALANCE SHEET DATA
Current assets Rs m18,877118,154 16.0%   
Current liabilities Rs m11,896462,260 2.6%   
Net working cap to sales %33.9-323.7 -10.5%  
Current ratio x1.60.3 620.8%  
Inventory Days Days3627 135.2%  
Debtors Days Days19847 425.1%  
Net fixed assets Rs m9,861113,727 8.7%   
Share capital Rs m341361 94.5%   
"Free" reserves Rs m12,331264,093 4.7%   
Net worth Rs m16,139264,454 6.1%   
Long term debt Rs m4,706242,206 1.9%   
Total assets Rs m33,146726,834 4.6%  
Interest coverage x1.61.7 96.9%   
Debt to equity ratio x0.30.9 31.8%  
Sales to assets ratio x0.60.1 424.9%   
Return on assets %8.111.1 73.1%  
Return on equity %6.919.4 35.4%  
Return on capital %12.310.3 119.2%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40215,110 29.1%   
Fx outflow Rs m3,1844,298 74.1%   
Net fx Rs m1,21910,813 11.3%   
CASH FLOW
From Operations Rs m2,437-159,666 -1.5%  
From Investments Rs m-6,265-17,677 35.4%  
From Financial Activity Rs m2,490186,503 1.3%  
Net Cashflow Rs m-1,3379,364 -14.3%  

Share Holding

Indian Promoters % 82.7 52.9 156.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 4.0 107.5%  
FIIs % 5.5 26.6 20.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 16.5 45.5%  
Shareholders   10,665 93,274 11.4%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS